Provided by Tiger Trade Technology Pte. Ltd.

Oncolytics Biotech Inc

0.5444
-0.0514-8.63%
Post-market: 0.55000.0056+1.03%19:58 EDT
Volume:1.12M
Turnover:624.20K
Market Cap:71.32M
PE:-1.69
High:0.6053
Open:0.6000
Low:0.5418
Close:0.5958
52wk High:1.36
52wk Low:0.5418
Shares:131.00M
Float Shares:126.58M
Volume Ratio:1.18
T/O Rate:0.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3215
EPS(LYR):-0.3000
ROE:-10187.64%
ROA:-211.24%
PB:-11.56
PE(LYR):-1.81

Loading ...

Company Profile

Company Name:
Oncolytics Biotech Inc
Exchange:
NASDAQ
Establishment Date:
1998
Employees:
29
Office Location:
4350 Executive Drive,Suite 325,San Diego,California,United States
Zip Code:
92121
Fax:
403 283 0858
Introduction:
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Directors

Name
Position
Jared Kelly
Chief Executive Officer and Director
Angela Holtham
Independent Director
Bernd R. Seizinger
Independent Director
Deborah M. Brown
Independent Director
James T. Parsons
Independent Director
Jonathan Rigby
Independent Director
Patricia Andrews
Independent Director
Stephen Glover
Independent Director
Wayne Pisano
Chair and Independent Director

Shareholders

Name
Position
Jared Kelly
Chief Executive Officer and Director
John McAdory
Chief Operating Officer
Kirk J. Look
Chief Financial Officer
Allison Hagerman
Chief Technology Officer
Andrew Aromando
Chief Business Officer
Thomas C. Heineman
Chief Medical Officer